Apolipoprotein E genotypes and the risk of Parkinson disease

Jianjun Gao, Xuemei Huang, Yikyung Park, Rui Liu, Albert Hollenbeck, Arthur Schatzkin, Richard Mailman, Honglei Chen

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We examined apolipoprotein E (ApoE) genotypes in relation to Parkinson's disease (PD) among 786 cases and 1537 controls, all non-Hispanic Caucasians. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from multivariate logistic regression models, adjusting for year of birth, sex, smoking status, daily caffeine intake, and family history of PD. Compared with participants with ApoE ε33, ε4 carriers (ε34/ε44) had significantly lower odds for having PD (OR, 0.75; 95% CI, 0.59-0.94; p = 0.01), whereas ε2 carriers (ε23/ε22) did not (OR, 0.95; 95% CI, 0.73-1.24; p = 0.71). Subgroup analyses showed similar results. In addition, we conducted a meta-analysis which confirmed our primary findings (ε34/ε44 vs ε33: OR, 0.90; 95% CI, 0.81-0.99; p = 0.024 and ε23/ε22 vs ε33: OR, 1.10; 95% CI, 0.97-1.23; p = 0.13). In PD patients, the prevalence of dementia appeared to be higher among ε4 carriers (compared with ε33: OR, 1.59; 95% CI, 0.98-2.58; p = 0.06), but lower among ε2 carriers (OR, 0.75; 95% CI, 0.40-1.42; p = 0.38), although neither test was statistically significant. Our study suggested that the ApoE ε4 allele may be associated with a lower PD risk among non-Hispanic Caucasians.

Original languageEnglish (US)
Pages (from-to)2106.e1-2106.e6
JournalNeurobiology of Aging
Volume32
Issue number11
DOIs
StatePublished - Jan 1 2011

Fingerprint

Apolipoproteins E
Parkinson Disease
Odds Ratio
Genotype
Confidence Intervals
Apolipoprotein E4
Logistic Models
Caffeine
Dementia
Meta-Analysis
Smoking
Alleles
Parturition

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Aging
  • Clinical Neurology
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Gao, J., Huang, X., Park, Y., Liu, R., Hollenbeck, A., Schatzkin, A., ... Chen, H. (2011). Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiology of Aging, 32(11), 2106.e1-2106.e6. https://doi.org/10.1016/j.neurobiolaging.2011.05.016
Gao, Jianjun ; Huang, Xuemei ; Park, Yikyung ; Liu, Rui ; Hollenbeck, Albert ; Schatzkin, Arthur ; Mailman, Richard ; Chen, Honglei. / Apolipoprotein E genotypes and the risk of Parkinson disease. In: Neurobiology of Aging. 2011 ; Vol. 32, No. 11. pp. 2106.e1-2106.e6.
@article{dc6e600b6c13499296f48d55d5fa4590,
title = "Apolipoprotein E genotypes and the risk of Parkinson disease",
abstract = "We examined apolipoprotein E (ApoE) genotypes in relation to Parkinson's disease (PD) among 786 cases and 1537 controls, all non-Hispanic Caucasians. Odds ratios (ORs) and 95{\%} confidence intervals (CIs) were derived from multivariate logistic regression models, adjusting for year of birth, sex, smoking status, daily caffeine intake, and family history of PD. Compared with participants with ApoE ε33, ε4 carriers (ε34/ε44) had significantly lower odds for having PD (OR, 0.75; 95{\%} CI, 0.59-0.94; p = 0.01), whereas ε2 carriers (ε23/ε22) did not (OR, 0.95; 95{\%} CI, 0.73-1.24; p = 0.71). Subgroup analyses showed similar results. In addition, we conducted a meta-analysis which confirmed our primary findings (ε34/ε44 vs ε33: OR, 0.90; 95{\%} CI, 0.81-0.99; p = 0.024 and ε23/ε22 vs ε33: OR, 1.10; 95{\%} CI, 0.97-1.23; p = 0.13). In PD patients, the prevalence of dementia appeared to be higher among ε4 carriers (compared with ε33: OR, 1.59; 95{\%} CI, 0.98-2.58; p = 0.06), but lower among ε2 carriers (OR, 0.75; 95{\%} CI, 0.40-1.42; p = 0.38), although neither test was statistically significant. Our study suggested that the ApoE ε4 allele may be associated with a lower PD risk among non-Hispanic Caucasians.",
author = "Jianjun Gao and Xuemei Huang and Yikyung Park and Rui Liu and Albert Hollenbeck and Arthur Schatzkin and Richard Mailman and Honglei Chen",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.neurobiolaging.2011.05.016",
language = "English (US)",
volume = "32",
pages = "2106.e1--2106.e6",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "11",

}

Gao, J, Huang, X, Park, Y, Liu, R, Hollenbeck, A, Schatzkin, A, Mailman, R & Chen, H 2011, 'Apolipoprotein E genotypes and the risk of Parkinson disease', Neurobiology of Aging, vol. 32, no. 11, pp. 2106.e1-2106.e6. https://doi.org/10.1016/j.neurobiolaging.2011.05.016

Apolipoprotein E genotypes and the risk of Parkinson disease. / Gao, Jianjun; Huang, Xuemei; Park, Yikyung; Liu, Rui; Hollenbeck, Albert; Schatzkin, Arthur; Mailman, Richard; Chen, Honglei.

In: Neurobiology of Aging, Vol. 32, No. 11, 01.01.2011, p. 2106.e1-2106.e6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Apolipoprotein E genotypes and the risk of Parkinson disease

AU - Gao, Jianjun

AU - Huang, Xuemei

AU - Park, Yikyung

AU - Liu, Rui

AU - Hollenbeck, Albert

AU - Schatzkin, Arthur

AU - Mailman, Richard

AU - Chen, Honglei

PY - 2011/1/1

Y1 - 2011/1/1

N2 - We examined apolipoprotein E (ApoE) genotypes in relation to Parkinson's disease (PD) among 786 cases and 1537 controls, all non-Hispanic Caucasians. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from multivariate logistic regression models, adjusting for year of birth, sex, smoking status, daily caffeine intake, and family history of PD. Compared with participants with ApoE ε33, ε4 carriers (ε34/ε44) had significantly lower odds for having PD (OR, 0.75; 95% CI, 0.59-0.94; p = 0.01), whereas ε2 carriers (ε23/ε22) did not (OR, 0.95; 95% CI, 0.73-1.24; p = 0.71). Subgroup analyses showed similar results. In addition, we conducted a meta-analysis which confirmed our primary findings (ε34/ε44 vs ε33: OR, 0.90; 95% CI, 0.81-0.99; p = 0.024 and ε23/ε22 vs ε33: OR, 1.10; 95% CI, 0.97-1.23; p = 0.13). In PD patients, the prevalence of dementia appeared to be higher among ε4 carriers (compared with ε33: OR, 1.59; 95% CI, 0.98-2.58; p = 0.06), but lower among ε2 carriers (OR, 0.75; 95% CI, 0.40-1.42; p = 0.38), although neither test was statistically significant. Our study suggested that the ApoE ε4 allele may be associated with a lower PD risk among non-Hispanic Caucasians.

AB - We examined apolipoprotein E (ApoE) genotypes in relation to Parkinson's disease (PD) among 786 cases and 1537 controls, all non-Hispanic Caucasians. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from multivariate logistic regression models, adjusting for year of birth, sex, smoking status, daily caffeine intake, and family history of PD. Compared with participants with ApoE ε33, ε4 carriers (ε34/ε44) had significantly lower odds for having PD (OR, 0.75; 95% CI, 0.59-0.94; p = 0.01), whereas ε2 carriers (ε23/ε22) did not (OR, 0.95; 95% CI, 0.73-1.24; p = 0.71). Subgroup analyses showed similar results. In addition, we conducted a meta-analysis which confirmed our primary findings (ε34/ε44 vs ε33: OR, 0.90; 95% CI, 0.81-0.99; p = 0.024 and ε23/ε22 vs ε33: OR, 1.10; 95% CI, 0.97-1.23; p = 0.13). In PD patients, the prevalence of dementia appeared to be higher among ε4 carriers (compared with ε33: OR, 1.59; 95% CI, 0.98-2.58; p = 0.06), but lower among ε2 carriers (OR, 0.75; 95% CI, 0.40-1.42; p = 0.38), although neither test was statistically significant. Our study suggested that the ApoE ε4 allele may be associated with a lower PD risk among non-Hispanic Caucasians.

UR - http://www.scopus.com/inward/record.url?scp=80052627014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052627014&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2011.05.016

DO - 10.1016/j.neurobiolaging.2011.05.016

M3 - Article

C2 - 21741729

AN - SCOPUS:80052627014

VL - 32

SP - 2106.e1-2106.e6

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 11

ER -